Table 4.
Cox proportional hazard modelling of recurrence-free survival times in the full study cohort
| Variable | Univariate analysis | ||
|---|---|---|---|
| P-value | Hazard ratio | (95% CI) | |
| Age >60 years | 0.438 | 1.54 | (0.52–4.58) |
| Waiting time ≥6 months | 0.063 | 2.91 | (0.94–9.00) |
| Pre-transplant AFP >25 ng/ml | 0.148 | 2.34 | (0.74–7.39) |
| Pre-transplant bridging therapy | 0.451 | 1.65 | (0.45–5.99) |
| Pathology staging | |||
| Exceeds Milan Criteria | 0.991 | Not estimated | |
| Exceeds expanded UCSF Criteria | <0.001 | 13.83 | (4.24–45.12) |
| Exceeds Milan, within expanded UCSF Criteria | 0.728 | 1.23 | (0.38–4.00) |
| Maximal tumour size > 3 cm | 0.110 | 2.62 | (0.81–8.50) |
| Tumour count > 3 | <0.001 | 59.13 | (7.67–456) |
| Presence of vascular invasion | 0.008 | 4.70 | (1.51–14.63) |
| Bilobar | |||
| On imaging and pathology | 0.064 | 3.12 | (0.94–10.37) |
| On pathology alone | 0.028 | 4.00 | (1.17–13.71) |
| Regional Review for Downstaging | 0.337 | 2.10 | (0.46–9.50) |
| Viable tumour on explant | 0.995 | Not estimated | |
95% CI, 95% confidence interval; AFP, alpha-fetoprotein; UCSF, University of California San Francisco.